Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:
					Select diseases Infectious Disease Novel Coronavirus Disease

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ABP-300 / Abpro Therap, BIO invest, Mabwell (Shanghai) Biosci
NCT04627584: A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19 Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: A Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody. Safety and immunogenicity data for COVID-19 treatment	Recruiting	2	150	RoW	MW33 injection, MW33 injection placebo	Mabwell (Shanghai) Bioscience Co., Ltd.	Covid19	05/21	09/21
ABP-160 / Abpro Therap
No trials found
ABP-500 / Abpro Therap
No trials found
ABP-201 / Abpro Therap, Abpro Bio
No trials found
ABP-110 / Abpro Therap
No trials found
ABP-150 / Abpro Therap
No trials found